Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Due Buron

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Neurology|March 7, 2021
Late-onset MS is associated with an increased rate of reaching disability milestonesMads Albrecht Andersen, Mathias Due Buron, Melinda Magyari
Frontiers in Neurology|April 4, 2022
Aging With Multiple Sclerosis: Age-Related Factors and Socioeconomic RisksMalthe Faurschou Wandall-Holm, Mads Albrecht Andersen, Mathias Due Buron, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 13, 2021
Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort studyMathias Due Buron, Tomas Kalincik, Finn Sellebjerg, et al.
Multiple Sclerosis and Related Disorders|December 30, 2019
Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-βMathias Due Buron, Melinda Magyari, Thor Ameri Chalmer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 10, 2022
Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosisMalthe Faurschou Wandall-Holm, Mathias Due Buron, Tine Iskov Kopp, et al.
Ugeskrift for Laeger|November 13, 2024
Maria Dons, Mathias Due Buron, Julie Maria Hejgaard Laursen, et al.
Multiple Sclerosis and Related Disorders|May 8, 2025
Socioeconomic impact of initial high vs. moderate efficacy disease-modifying therapy in multiple sclerosis: Effects on labor market affiliationRolf Pringler Holm, Elisabeth Framke, Luigi Pontieri, et al.
Multiple Sclerosis and Related Disorders|April 14, 2023
Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-upMathias Due Buron, Jeppe Romme Christensen, Luigi Pontieri, et al.
Plos One|May 18, 2021
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis RegistryViktoria Papp, Mathias Due Buron, Volkert Siersma, et al.
Neurology|March 17, 2019
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort studyMathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Neurology|March 7, 2021
Late-onset MS is associated with an increased rate of reaching disability milestonesMads Albrecht Andersen, Mathias Due Buron, Melinda Magyari
Frontiers in Neurology|April 4, 2022
Aging With Multiple Sclerosis: Age-Related Factors and Socioeconomic RisksMalthe Faurschou Wandall-Holm, Mads Albrecht Andersen, Mathias Due Buron, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 13, 2021
Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort studyMathias Due Buron, Tomas Kalincik, Finn Sellebjerg, et al.
Multiple Sclerosis and Related Disorders|December 30, 2019
Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-βMathias Due Buron, Melinda Magyari, Thor Ameri Chalmer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 10, 2022
Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosisMalthe Faurschou Wandall-Holm, Mathias Due Buron, Tine Iskov Kopp, et al.
Ugeskrift for Laeger|November 13, 2024
Maria Dons, Mathias Due Buron, Julie Maria Hejgaard Laursen, et al.
Multiple Sclerosis and Related Disorders|May 8, 2025
Socioeconomic impact of initial high vs. moderate efficacy disease-modifying therapy in multiple sclerosis: Effects on labor market affiliationRolf Pringler Holm, Elisabeth Framke, Luigi Pontieri, et al.
Multiple Sclerosis and Related Disorders|April 14, 2023
Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-upMathias Due Buron, Jeppe Romme Christensen, Luigi Pontieri, et al.
Plos One|May 18, 2021
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis RegistryViktoria Papp, Mathias Due Buron, Volkert Siersma, et al.
Neurology|March 17, 2019
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort studyMathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, et al.
Pageof 2